Search Browse Earnings

Evofem Biosciences, Inc.

OTC:EVFM

Pharmaceutical Preparations·SAN DIEGO, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Evofem Biosciences, Inc. — SlamSEC

Revenue

$18.2M

+8.2% YoY

FY 2024

Adj. EBITDA

-$16.8M

-92.4% margin

FY 2024

Net Income

$53.0M

290.8% margin

FY 2024

EPS (Diluted)

$0.05

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$2.8M

FY 2023

Total Debt

$7.3M

FY 2016

Net Debt

$4.6M

FY 2016

Enterprise Value

—

Debt / EBITDA

-0.3x

FY 2024

EV / EBITDA

—

Employees

—

CEO

Pelletier Saundra L

CFO

Zhang Yan